WASHINGTON (dpa-AFX) - Aim ImmunoTech Inc. (AIM) announced positive preliminary findings on Wednesday, showing that pairing Ampligen or rintatolimod with Keytruda in treating recurrent ovarian cancer could have a strong combined effect.
The initial results from Phase 2 trial revealed a 45% Objective Response Rate when Ampligen, pembrolizumab, and cisplatin were used in patients with platinum-sensitive recurrent ovarian cancer.
AIM's CEO, Thomas Equels, noted that the data suggests a significant increase in treatment efficacy when Ampligen is added to pembrolizumab for recurrent ovarian cancer, with potential benefits for various cancer types.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
